All these evidences reveal the role of PLCβ1/PKCα signaling in erythroid differentiation on del(5q) low-risk MDS patients responding to lenalidomide, and thus opening the way to innovative targeted therapies. This evidence concerns the gene PLCB1 and myelodysplastic syndrome.